Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBITDA (2020 - 2025)

Historic EBITDA for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.

  • Pliant Therapeutics' EBITDA rose 5334.47% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.3 million, marking a year-over-year increase of 1136.75%. This contributed to the annual value of -$210.3 million for FY2024, which is 3225.43% down from last year.
  • Pliant Therapeutics' EBITDA amounted to -$26.3 million in Q3 2025, which was up 5334.47% from -$43.5 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' EBITDA registered a high of -$22.8 million during Q1 2021, and its lowest value of -$56.3 million during Q1 2025.
  • Over the past 5 years, Pliant Therapeutics' median EBITDA value was -$36.9 million (recorded in 2023), while the average stood at -$37.8 million.
  • Per our database at Business Quant, Pliant Therapeutics' EBITDA plummeted by 30598.79% in 2021 and then surged by 5334.47% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' EBITDA stood at -$24.7 million in 2021, then crashed by 39.98% to -$34.6 million in 2022, then dropped by 12.42% to -$38.9 million in 2023, then fell by 29.34% to -$50.3 million in 2024, then skyrocketed by 47.74% to -$26.3 million in 2025.
  • Its EBITDA was -$26.3 million in Q3 2025, compared to -$43.5 million in Q2 2025 and -$56.3 million in Q1 2025.